D-36 | Did Covid Affect Cath Lab Quality?

BackgroundThe pandemic (P) has been disruptive to many health care activities. Quality is an ongoing process and the presence of a robust system may assist in maintaining consistent performance. ACE reviews cath labs over time and this analysis was undertaken to determine whether P has affected quality metrics.MethodsRandomly selected cases (RCR) from each site are reviewed by blinded, independent interventional cardiologists and all data are recorded on a standard case report form. Chart reviews (CR) and site visit (SV) data were also reviewed. Each review was identified as either pre covid (PC) or covid (C) and initial (1) or reaccreditation (R) review. The data from R visits PC were used as the baseline. Statistical analysis was performed using JMP pro (version 16.2.0, SAS Institute Cary NC).ResultsSix facilities were identified as having both PC and C reviews. The majority were regulatory reviews and did not have onsite surgery. The focus was on PCI procedures for this reason. Data from RCR are shown in Table 1. The CR were consistent with the findings from the case reviews and showed a higher rate of repeat hospitalization, death and kidney disease within 30 days. The SV show that RCR, monitoring of normal angiogram rates and reporting were less likely to occur during C.ConclusionsDisclosuresJ. J. Marshall: Abiomed: DSMB; B. H. Weiner Nothing to disclose. J. E. Cigarroa Nothing to disclose. M. J. Cowley Nothing to disclose. BackgroundThe pandemic (P) has been disruptive to many health care activities. Quality is an ongoing process and the presence of a robust system may assist in maintaining consistent performance. ACE reviews cath labs over time and this analysis was undertaken to determine whether P has affected quality metrics. The pandemic (P) has been disruptive to many health care activities. Quality is an ongoing process and the presence of a robust system may assist in maintaining consistent performance. ACE reviews cath labs over time and this analysis was undertaken to determine whether P has affected quality metrics. MethodsRandomly selected cases (RCR) from each site are reviewed by blinded, independent interventional cardiologists and all data are recorded on a standard case report form. Chart reviews (CR) and site visit (SV) data were also reviewed. Each review was identified as either pre covid (PC) or covid (C) and initial (1) or reaccreditation (R) review. The data from R visits PC were used as the baseline. Statistical analysis was performed using JMP pro (version 16.2.0, SAS Institute Cary NC). Randomly selected cases (RCR) from each site are reviewed by blinded, independent interventional cardiologists and all data are recorded on a standard case report form. Chart reviews (CR) and site visit (SV) data were also reviewed. Each review was identified as either pre covid (PC) or covid (C) and initial (1) or reaccreditation (R) review. The data from R visits PC were used as the baseline. Statistical analysis was performed using JMP pro (version 16.2.0, SAS Institute Cary NC). ResultsSix facilities were identified as having both PC and C reviews. The majority were regulatory reviews and did not have onsite surgery. The focus was on PCI procedures for this reason. Data from RCR are shown in Table 1. The CR were consistent with the findings from the case reviews and showed a higher rate of repeat hospitalization, death and kidney disease within 30 days. The SV show that RCR, monitoring of normal angiogram rates and reporting were less likely to occur during C. Six facilities were identified as having both PC and C reviews. The majority were regulatory reviews and did not have onsite surgery. The focus was on PCI procedures for this reason. Data from RCR are shown in Table 1. The CR were consistent with the findings from the case reviews and showed a higher rate of repeat hospitalization, death and kidney disease within 30 days. The SV show that RCR, monitoring of normal angiogram rates and reporting were less likely to occur during C. Conclusions DisclosuresJ. J. Marshall: Abiomed: DSMB; B. H. Weiner Nothing to disclose. J. E. Cigarroa Nothing to disclose. M. J. Cowley Nothing to disclose. J. J. Marshall: Abiomed: DSMB; B. H. Weiner Nothing to disclose. J. E. Cigarroa Nothing to disclose. M. J. Cowley Nothing to disclose.